By
Drug Target Review2024-07-22T12:00:32
The approach precisely and durably corrects the CFTR mutation in human lung cells, which could lead to superior treatments.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-01T13:30:00Z
Contributor Carrie Maynard and Dr Veronica Fowler
2024-01-26T13:22:42
Sponsored by bit.bio
2023-03-08T16:29:20
Sponsored by Bio-Techne
2023-03-20T13:41:33
Sponsored by Bio-Techne
2023-03-23T14:46:21
Sponsored by Bio-Techne
2023-07-04T10:05:58
Sponsored by Revvity
2024-03-08T10:00:25
Sponsored by Molecular Devices
Site powered by Webvision Cloud